Intra-arterial therapies for hepatocellular carcinoma: Where do we stand?

Eleni A Liapi, Jean Francois H Geschwind

Research output: Contribution to journalArticle

Abstract

Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.

Original languageEnglish (US)
Pages (from-to)1234-1246
Number of pages13
JournalAnnals of Surgical Oncology
Volume17
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Therapeutic Embolization
Radiotherapy
Ethiodized Oil
Yttrium
Drug Therapy
Iodine
Meta-Analysis
Catheters
Clinical Trials
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Intra-arterial therapies for hepatocellular carcinoma : Where do we stand? / Liapi, Eleni A; Geschwind, Jean Francois H.

In: Annals of Surgical Oncology, Vol. 17, No. 5, 05.2010, p. 1234-1246.

Research output: Contribution to journalArticle

Liapi, Eleni A ; Geschwind, Jean Francois H. / Intra-arterial therapies for hepatocellular carcinoma : Where do we stand?. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 5. pp. 1234-1246.
@article{b75879e3b7d4492daea2b12328469530,
title = "Intra-arterial therapies for hepatocellular carcinoma: Where do we stand?",
abstract = "Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.",
author = "Liapi, {Eleni A} and Geschwind, {Jean Francois H}",
year = "2010",
month = "5",
doi = "10.1245/s10434-010-0977-4",
language = "English (US)",
volume = "17",
pages = "1234--1246",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Intra-arterial therapies for hepatocellular carcinoma

T2 - Where do we stand?

AU - Liapi, Eleni A

AU - Geschwind, Jean Francois H

PY - 2010/5

Y1 - 2010/5

N2 - Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.

AB - Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.

UR - http://www.scopus.com/inward/record.url?scp=77952084899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952084899&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-0977-4

DO - 10.1245/s10434-010-0977-4

M3 - Article

C2 - 20405328

AN - SCOPUS:77952084899

VL - 17

SP - 1234

EP - 1246

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -